Pro Medicus Limited (PMC) Q4 2025 Earnings Report
DE:PMC Q4 2025 EPS Results
- Actual EPS
- EUR 0.38
- Consensus EPS
- EUR 0.36
- Beat/Miss
- Beat by +EUR 0.02
- One Year Ago EPS
- EUR 0.28
DE:PMC Q4 2025 Revenue Results
- Actual Revenue
- EUR 72.38M
- Expected Revenue
- EUR 72.38M
- Beat/Miss
- Beat by +EUR 5,000.984
- YoY Revenue Growth
- +32.50%
Earnings Announcement Details
- Quarter
- Q4 2025
- Date
- 08/13/2025
- Time
- After Close
- Conference Call
- Wednesday, August 13, 2025
Pro Medicus Limited's next earnings date is estimated for February 16, 2027, based on past reporting schedules.
Q4 2025 Earnings Call Audio
Q4 2025 Earnings Slide Deck
Q4 2025 Earnings Call Summary
The earnings call highlighted strong financial performance with record revenue and profit growth, significant contract wins, and advancements in cloud and AI technology. However, challenges remain in expanding market penetration outside North America and navigating a competitive landscape.
During the Pro Medicus Limited Full Year Results Briefing, CEO Dr. Sam Hupert highlighted significant achievements for FY '25, with key financial metrics showing substantial improvement. Revenue increased by nearly 32%, profit after tax rose by approximately 40%, and underlying EBIT also saw a 40% rise. Margins improved from mid-72% to 74%, leading to a 36% increase in retained earnings. The company announced a fully franked dividend of $0.30 per share for the half, a 37.5% increase. Pro Medicus secured seven contracts worth $520 million, renewed two large contracts totaling $130 million, and achieved $39 million in upgrades. The company's forward revenue increased from the low $600 million range to $948 million over a five-year period. Additionally, Pro Medicus made strides in cloud deployment, research collaborations, and expanded its product offerings, setting a strong foundation for future growth.
- Significant Revenue and Profit GrowthRevenue increased by just under 32%, profit after tax rose approximately 40%, and underlying EBIT was up around 40%. Margins increased from mid-72s to 74%.
- Record Year for Sales and ContractsWon 7 contracts totaling $520 million, renewed 2 large contracts worth $130 million, and secured upgrades for additional products with existing clients for a total of $39 million.
- Expansion in North AmericaNorth America remains the largest market, contributing to 90% of revenue. Significant contracts included a $330 million contract with Trinity and $57 million with BayCare.
- Advancements in Cloud and AIPro Medicus is the only company with a 100% full cloud solution at scale, with the ability to work across AWS, Azure, and Google GCP. New AI initiatives include a breast cancer detection algorithm developed with NYU.
- Strategic Partnerships and CollaborationsResearch collaboration agreement signed with UCSF, adding to partnerships with Mayo and NYU.
DE:PMC Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Feb 16, 2027 | 2027 (Q2) | 0.53- | 1.02 | ― | ― |
| Aug 17, 2026 | 2026 (Q4) | 0.440.46 | 0.38 | 22.11% (+0.08) | |
| Feb 11, 2026 | 2026 (Q2) | 0.411.02 | 0.31 | 231.17% (+0.71) | |
| Aug 13, 2025 | 2025 (Q4) | 0.360.38 | 0.28 | 34.67% (+0.10) | |
| Feb 12, 2025 | 2025 (Q2) | 0.310.31 | 0.22 | 42.77% (+0.09) | |
| Aug 13, 2024 | 2024 (Q4) | 0.260.28 | 0.21 | 35.95% (+0.07) | |
| Feb 14, 2024 | 2024 (Q2) | 0.220.22 | 0.16 | 33.08% (+0.05) | |
| Aug 14, 2023 | 2023 (Q4) | 0.210.21 | 0.14 | 49.77% (+0.07) | |
| Feb 14, 2023 | 2023 (Q2) | 0.160.16 | 0.12 | 31.98% (+0.04) | |
| Aug 17, 2022 | 2022 (Q4) | 0.200.14 | 0.1 | 33.94% (+0.04) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
